Buprofezin is an insecticide with a thiadiazine structure. This active substance was proposed for inclusion in Annex I of the Directive 91/414/EEC in 2005, but in the Draft Assessment Report (DAR), the Rapporteur Member State (Finland) identified a data gap: "new studies for in vitro and in vivo chromosomal aberration assays were required because the potency to cause chromosomal aberrations was insufficiently studied through the submitted information".
In the light of the results of the new genotoxicity studies the carcinogenic potential of buprofezin was reassessed by the Pesticide Risk Assessment Peer Review (PRAPeR) expert meeting (EFSA) but a conclusion could not be reached. Therefore the Scientific Panel on Plant Protection Products and their Residues (PPR Panel) of EFSA was asked for an opinion by the PRAPeR Unit on the genotoxic and carcinogenic potential of buprofezin in the context of the human risk assessment.
The PPR Panel re-evaluated the long-term toxicity/carcinogenicity studies on buprofezin.
Two studies on the carcinogenicity of buprofezin were conducted in mice and rats. The PPR Panel concluded that the differences from the EU guidelines in the protocol for the carcinogenicity study in rats were not such as to prevent its use for the evaluation of the carcinogenic potential of the test compound. In mice and rats, neither the nature nor the incidence of tumours was affected by the administration of buprofezin.
The PPR Panel re-evaluated the genotoxicity studies on buprofezin.
Buprofezin did not show any genotoxic potential in an acceptable, comprehensive battery of in vitro and in vivo tests evaluating different genetic endpoints of genotoxic damage (gene mutation, chromosome mutation, DNA damage and repair) using bacteria and mammalian systems.
A new in vitro chromosomal aberration test in cultured Chinese hamster lung cells (CHL) did not show any increase in structural or numerical chromosomal aberrations at any concentration of buprofezin, up to those that were cytotoxic, compared to the concurrent or historical controls.
It is the view of the PPR Panel that a recent in vivo micronucleus test on bone marrow is not interpretable due to the use of non standard methodology and that it does not contribute to the evaluation of the genotoxicity of buprofezin.
The PPR Panel concluded on the basis of an adequate range of suitably conducted tests of genotoxicity both in vitro and in vivo that there is no evidence that buprofezin is genotoxic. 
BACKGROUND
Buprofezin (2-tert-butylimino-3-isopropyl-5-phenylperhydro-1,3,5-thiadiazin-4-one) is an insecticide with a thiadiazine structure. Its uses are on citrus fruit, tomato and lettuce. Buprofezin is a chitin synthesis inhibitor and it controls various pests such as whitefly and scales. The application rate in intended uses varies between 0.20 -1.0 kg a.i./ha.
It is an active substance of the list 3A. The draft assessment report (DAR) was finalised in May 2005.
Inclusion in Annex I of the Directive 91/414 was proposed, but in the DAR, the RMS (Finland) identified a data gap (Vol.1, lev.4): "new studies for in vitro and in vivo chromosomal aberration assays were required because the potency to cause chromosomal aberrations was insufficiently studied through the submitted information".
In September 2006 the RMS submitted an addendum (addendum 1 to vol. 3) summarising new studies provided by the applicant. In particular, a new micronucleus test in the bone marrow of mouse (Inagaki 2006b) showed that buprofezin induced micronuclei in the erythrocytes of mouse bone marrow when administered by oral gavage once daily for two consecutive days.
This finding was supported by the results of a published in vivo study (mouse bone marrow cells). The in vivo results were not supported by the in vitro data that were submitted (Chinese hamster lung cells) but in a published study buprofezin showed aneugenic effects in somatic cells in vitro (Syrian hamster embryo cells). Buprofezin did not induce chromosomal aberrations in germ cells in vivo (mouse spermatocytes) in a published study. Buprofezin was not mutagenic or genotoxic in acceptable studies (two point mutation assays and unscheduled DNA synthesis) evaluated previously in the DAR.
Buprofezin was discussed in an experts' meeting in June 2007.
Based on the findings in the new in vivo micronucleus test, the long term toxicity/carcinogenicity study on rats was re-considered. According to the evaluation of the RMS it should be considered as a supplementary study only. Furthermore, the study showed a mortality of > 50%, possibly making the study not acceptable. The meeting agreed that the long term rat study was fundamentally flawed, and that the incidence of tumours could not be clearly established based on this study.
It was noted however that the JMPR (Joint FAO/WHO Meetings on Pesticide Residues) did not consider the study invalid and also that EPA had used it for their evaluation of the compound.
The meeting agreed that there were two data gaps:
1. A guideline compliant 24-months rat carcinogenicity study.
2. A guideline compliant in vivo germ cell mutagenicity study.
The experts concluded that an ADI and AOEL could not be established without conclusive information on the long-term effects in rats.
Therefore, it was decided to forward a question to the PPR Panel
TERMS OF REFERENCE
The Scientific Panel on Plant Protection Products and their Residues (PPR Panel) of EFSA was asked for an opinion on the genotoxic and carcinogenic potential of buprofezin in the context of the human risk assessment. The following questions were identified: Buprofezin is an insecticide with a thiadiazine structure. It acts by inhibiting chitin biosynthesis and subsequent cuticle deposition. It also has effects on the hormone levels of nymphs associated with moulting and on prostaglandin synthesis. It is not translocated in plants. It is for use on citrus fruit, tomato and lettuce.
Following oral administration to rats, buprofezin was rapidly absorbed, biotransformed and relatively rapidly eliminated, predominantly in faeces. The compound was distributed in blood, liver, kidney and urinary bladder and in lesser amounts in other organs after oral administration. The maximum concentration in blood was observed at 9 hours and in other tissues and organs at 5-9 hours after administration. The biological half-life of the first phase of elimination was 13 hours, and the half-life of the second phase was 60 hours. Over 90% of radioactivity was eliminated within 48 hours. In total, 70-74% of the dose was recovered in faeces and 21-25% in urine. Excretion into bile was about 33%. Based on the excretion into urine and bile, it was estimated that approximately 50% of buprofezin was absorbed. There was no indication of accumulation of buprofezin or its metabolites in the tissues. Radioactivity in the body was less than 1% of the administered dose seven days after dosing.
Hydroxylation of the phenyl ring and oxidation of the t-butyl group and sulphur atom, with thiadiazine ring opening were the main metabolic routes.
Buprofezin was of low acute toxicity by oral, dermal or inhalation routes in the rat. The oral LD 50 in rats is reported as 3847 and 2278 mg/kg bw (Komatsu, 1996 cited in the DAR) and 2198 and 2355 mg/kg bw (Ebino and Shirasu, 1981 cited in the DAR) in males and females, respectively. Clinical signs after high oral doses included decreased locomotor activity, tremor, lacrimation, abnormal gait and urinary incontinence. Buprofezin caused slight irritation to the rabbit eye but not to rabbit skin and it is regarded as non-irritant according to EC classification criteria. Buprofezin was not a skin sensitizer in the guinea pig Maximisation Test.
The liver and thyroid were identified as target organs in short term and long term toxicity studies. The most prominent effects in subchronic studies were increased liver and thyroid weights accompanied by histological and clinical chemistry findings, decreased plasma glucose and serum triglyceride levels at higher doses. In a 90-day feeding study, Sprague-Dawley rats (Jcl:SD) (10 animals/sex/group) received buprofezin (purity: >99%) at concentrations of 0, 40, 200, 1000 or 5000 ppm (mg/kg feed) (actual concentrations were 46, 185, 982 and 4555 ppm). Food consumption and body weights were slightly reduced at and above 1000 ppm; food consumption was slightly decreased also at 200 ppm. At ≥ 1000 ppm, liver and thyroid gland were enlarged and the absolute and relative organ weights were increased. Enlargement of the hepatocytes in the central to the middle zone of the liver lobules was found. Increased thickening and hyperplasia of the follicular epithelial cells of the thyroid were evident in top dosed animals and in some animals in the 1000 ppm group. The concentrations of serum cholesterol and phospholipids were elevated; the plasma glucose and serum triglyceride levels were decreased at 1000 and 5000 ppm. Haemoglobin concentrations, haematocrit values and erythrocyte counts in the blood were slightly decreased in the 5000-ppm group. The NOAEL was 40 ppm (equal to 3.4 mg/kg bw/day for males and 4.1 mg/kg bw/day for females) based on decreased food consumption and clinical chemistry (mainly glucose and triglycerides) parameters at higher doses (Watanabe, 1986 cited in the DAR).
In a 90-day oral study in dogs, subdued behaviour, reduced food consumption and body weight gain, slight ataxia and slight abdominal distension were noted mainly at 300 mg/kg bw/day. High alanine aminotransferase activities were also found at 300 mg/kg bw/day. Plasma alkaline phosphatase activity was raised in males at 50 mg/kg bw/day and in all animals at 300 mg/kg bw/day. Liver, kidney and thyroid weights were increased at 50 mg/kg bw/day and above. A homogeneous appearance of hepatocyte cytoplasm was found at and above 50 mg/kg bw/day and intracytoplasmic eosinophilic bodies were seen in the hepatocytes in all dogs at 300 mg/kg bw/day, and in one female at 50 mg/kg bw/day. The NOAEL was 10 mg/kg bw/day based on clinical signs and liver and thyroid toxicity (increased plasma alkaline phosphatase and alanine aminotransferase activities, increased organ weights and histopathological changes in the liver) at higher doses (Broadmeadow, 1986 cited in the DAR) In line with these results, in a 107-week study in dogs with oral administration of 0, 2, 20 and 200 mg/kg bw/day of buprofezin (purity, >99%), increased liver weight associated with enlargement of centrilobular hepatocytes and bile duct hyperplasia were seen at and above 20 mg/kg bw/day. Increased plasma alkaline phosphatase activity was seen in animals in high and intermediate dose groups, and an increase in plasma alanine aminotransferase activity was recorded in top-dosed animals. Reduced serum thyroxine levels were noted in dogs receiving the high dose, while tri-iodothyronine and protein bound iodine concentrations were unaffected. The NOAEL was 2 mg/kg bw/day in this study (Cummins, 1982 cited in the DAR) Buprofezin (purity 99.5-99.8%) was investigated in a comprehensive and acceptable battery of in vitro and in vivo tests evaluating different endpoints of genotoxic damage (gene mutation, chromosome mutation, DNA damage and repair) in bacteria and mammalian systems. The compound did not show any genotoxic effect, After long term exposure, no carcinogenic effects were reported (see below).
The reproductive toxicity of buprofezin was investigated in a two-generation study and in two prenatal-developmental toxicity studies. Toxicity was observed in the offspring only at dose levels inducing maternal toxicity. No teratogenicity was seen in any species.
In the two-generation study, parental animals receiving the highest dose of buprofezin (1000 ppm equal to 66.0 and 93.1 mg/kg bw in males and females respectively) showed increased liver, kidney and adrenal weights. Increased kidney and liver weights were observed in males and increased adrenal, pituitary and liver weights in females. No histopathological changes were observed in any organ, including those showing changes in weight gain and reproductive organs. Body weight gains of F 2 pups were decreased at 1000 ppm, although mean body weights were not significantly different from controls. The NOAEL for adults was 100 ppm equal to 6.46 mg/kg bw/day for males and 9.21 mg/kg bw/day for females, based on the increased organ weights at 1000 ppm. The NOAEL for offspring was also 100 ppm based on reduced body weight gain of pups. The NOAEL for reproductive toxicity was 1000 ppm equal to 66-74 mg/kg bw/days for males and 93-100 mg/kg bw/day for females, the highest dose tested. Based on this reproductive toxicity study in rat, the test substance should not be classified as toxic for reproduction or fertility (Toyohara, 1997 cited in the DAR).
In teratogenicity studies, buprofezin did not induce specific malformations or increase the incidence of spontaneous malformations at doses up to and including the highest tested in rats or rabbits. Maternal toxicity was evidenced by reduced food intake, decreased body weight, and clinical signs at the highest dose of 800 mg/kg bw/day in rats. In rabbits, body weight gain and food consumption were reduced at 250 mg/kg bw/day. One female receiving 50 mg/kg bw/day aborted on day 25 after insemination and two females receiving 250 mg/kg bw/day showed resorptions of the entire litter. The PPR panel considered that these abortions and resorptions were incidental to treatment. No other treatment-related effects were found. The NOAEL for maternal toxicity was 200 mg/g bw/day for rats and 50 mg/kg bw/day for rabbits (Tesh et al., 1987 cited in the DAR).
Revaluation of long-term toxicity/carcinogenicity studies
The chronic toxicity and potential carcinogenicity of buprofezin were investigated in 24 month dietary studies in rats and mice.
Question 1
Are the long-term/carcinogenicity studies of buprofezin of sufficient quality to enable an evaluation of its carcinogenic potential?
24-Month chronic toxicity /carcinogenicity dietary study in mice
The 24-month chronic toxicity/carcinogenicity dietary study in mice (Yoshida, 1990 cited in the DAR) essentially followed the EU-guidelines. The main difference was fewer sampling intervals than specified in the guidelines (B.33 (Annex V Directive 67/548/EEC); OECD 453,1981).
Groups of 70 male and 70 female SPF ICR-Crj mice (Crj:CD-1) were administered buprofezin (purity: 99.5%) as a dietary admixture at concentrations of 0, 20, 200, 2000 and 5000 ppm over a period of 104 weeks. Mean consumption of buprofezin was 0, 1.82, 17.9, 190 and 481 mg/kg bw/day in males, and 0, 1.89, 17.9, 191 and 493 mg/kg bw/day in females. Satellite groups of 10 animals/sex/group were treated in a similar manner for 52 weeks. Determinations of concentration and homogeneity of test compound in the diet were made at intervals of three months. Diet analysis revealed satisfactory consistency in concentration and homogeneity of the test compound. Ten animals from each sex/group were subjected to urinalysis, haematology and blood chemistry and terminated for pathological examinations at each of weeks 52 and 104. Gross pathological examination was performed on all animals. Organs weights were recorded in each animal subjected to interim or terminal kill.
The mortality of the treated groups of both sexes was comparable to that of the controls.
In the 5000 ppm groups retarded growth, decreased specific gravity of urine, reduced levels of protein in the urine, elevation of platelet and lymphocyte counts (after 104 weeks of treatment), and increased absolute and relative liver weight were seen in both sexes. Females showed slight anaemia after 52 weeks of treatment. The total blood cholesterol was increased at week 52 for females and at week 104 for males. Statistically significant increased incidence of diffuse hepatocellular swelling (at 104 weeks: 42/80 in males and 24/80 in females, in contrast to 9/80 in males and 2/80 in females in controls; increased incidence in females during interim kill after 52 weeks: 6/10 in contrast to 0/10 in controls), and of centrilobular hepatocellular swelling (at 104 weeks: 13/80 in male and 12/80 in female compared to 3/80 in both sexes of controls; increased incidence in both sexes during interim kill after 52 weeks: 6/10 in males and 4/10 in females in contrast to 0/10 in both sexes of controls ) and hepatocellular hyperplasia (27/80 in males and 8/80 in females compared to 12/80 in males and 2/80 in females of controls groups) were also observed.
In the 2000 ppm groups slightly retarded growth and an increase in the absolute and relative liver weights after 52 weeks were recorded in both sexes. The total blood cholesterol was increased at week 52 for females. A statistically significant increased incidence of centrilobular hepatocellular swelling at 104 weeks (10/80 in males, 15/80 in females compared to 3/80 in control group of both sexes; in females during interim kill after 52 weeks) and hepatocellular hyperplasia (13/80 vs. 12/80 in males and 9/80 vs. 2/80 in females) were observed. In the 200 ppm group an increase in liver weight was noted in males at week 52.
Tumour incidence. The incidence of hepatocellular adenomas was increased in the 5000-ppm group of females (8/80 vs. 2/80) but was within the historical control range. The incidence of hepatocellular carcinomas in the females receiving 2000 and 5000 ppm (4/80), was slightly above the historical range of 0-3/80, but was not significantly different from that in the concurrent controls (3/80). The combined incidence of these adenomas and hepatocellular carcinomas was not statistically significantly different from controls (12/80 and 5/80, respectively). The PPR Panel therefore concluded that buprofezin was not carcinogenic to the liver of mice.
The overall incidence of lung adenomas and carcinomas in males in the 200 and 5000-ppm groups was significantly higher than that of the controls. The combined incidences were 17/80, 26/80, 29/80 23/80 and 30/80 for 0, 20, 200, 2000 and 5000 ppm, respectively. There was no obvious relationship with dose, the incidences were within the historical control range and the concurrent controls were low compared to historical controls (Yoshida, 1990) . Hence, the PPR Panel concluded that buprofezin had no effect on the incidence of lung tumours in the mouse.
The PPR Panel concluded that no evidence of carcinogenic potential of buprofezin was observed in this study.
The NOAEL based on liver effects was 20 ppm (male), equal to 1.82 mg/kg bw/day and 200 ppm (females), equal to 17.9 mg/kg bw/day.
24-Month chronic toxicity/carcinogenicity dietary study in rats
The 24-month Combined Chronic Toxicity/Carcinogenicity Study in rats (Watanabe et al., 1982 cited in the DAR) was accepted by the RMS as a study of chronic toxicity but was considered as providing only additional information for the evaluation of the potential carcinogenicity of the test compound. The Draft Assessment Report (DAR, 2005) highlighted: "The study seems to essentially comply with the EU-guideline 67/548/EEC, Annex V, B.30., except the examination interval should have been 3 months, six months, and thereafter at approximately six month intervals. In this study, interim examinations at 3 months and at 18 months were not reported. For a combined study, the number of animals was too low and there were fewer sampling intervals than stated in the guideline. For a negative test result to be acceptable not more than 10% of any group may be lost from the experiment due to autolysis, cannibalism or management problems, and the survival of all groups must be not less than 50% at 24 months for rats. In this study, the mortality was high, up to 68%" and concluded "The study is acceptable for evaluation of chronic toxicity and acceptable to give additional information for evaluation of oncogenicity."
This study was designed in accordance with the guidance provided by the Japanese Ministry of Agriculture, Fisheries and Forestry, in 1972. The scientific rigour of the study was strengthened to facilitate the acceptability of the study to international regulatory authorities at that time. The methodology employed at the time was considered to be the best practice as internationally recognized guidelines were unavailable. Neither OECD guideline Test No. 453: Combined Chronic Toxicity/Carcinogenicity Studies (adopted 12 May 1981) nor Directive 87/302/EEC were available at the time that the study was planned. The relevant EPA (Environmental Protection Agency) guideline (edition of Nov.1984, 83-1 & 83-2) was also unavailable.
Commission Directive 94/79/EC Article 1(4) amending 91/414/EEC reports that "when reference is made in this Annex to an EEC Method which consists in the transposal of a method developed by an international organization (e.g. OECD), Member States may accept that the required information is generated according to the latest version of that method if at the initiation of the studies the EEC Method has not yet been updated". This concept should be applied to the 24 Month Rat Study, in consideration of the date at which the study was initiated.
It is also important to consider that:
• The test compound has been authorized in a number of EU Member States that considered acceptable the available long-term carcinogenicity studies
• JMPR (1991) considered the studies as acceptable and concluded that there was no convincing evidence of carcinogenicity in rodents.
• EPA accepted the studies and concluded that there was no evidence of carcinogenicity.
The Report for Buprofezin 24 month combined rat toxicity/carcinogenicity study and the report on the assessment, under current pathology diagnostic guidelines, of the incidence of and toxicological significance of liver and thyroid lesions, were revaluated by the PPR Panel.
Groups of 40 male and 40 female cl: SD rats, 5 weeks of age were exposed to buprofezin (purity: >99%) mixed in a powdered CE-2 chow in doses of 0, 5, 20, 200 and 2000 ppm for 24 months. Additional groups of 5 and 10 rats of each sex were exposed in a similar manner for 6 and 12 months respectively. Analysis of test diets showed that the actual concentrations were 3.9-6.5 ppm (first 2 months, 12 ppm), 16.5-21 ppm (first 2 months, 26 ppm), 175-210 ppm and 1700-2000 ppm (last 2 month, 2300 ppm) respectively. The compound was stable in the diet for up to 120 days. The daily intake (total mean) of the test compound was equal to 0.26, 0.90, 8.71 and 89.5 mg/kg bw/day for males and 0.33, 1.12, 11.19 and 114.7 mg/kg bw/day for females.
Haematology, blood chemistry and urine analysis were performed at 6, 12 and 24 months of treatment. Necropsy was performed on all animals including those found dead or killed in extremis. Organ weights were determined at necropsy. Phenolsulfophthalein (PSP) and bromosulfophthalein (BSP) excretion tests were performed in 5 males and 5 females from control and 2000 ppm groups after 24 months of treatment.
All animals were subjected to histopathological examination. Those liver samples that showed treatment-related changes were examined by electron microscopy. .
As a combined chronic toxicity/carcinogenicity study, a number of differences from EU guidelines were identified: • In the study, there were groups of 40 males and 40 females for each dose and the concurrent controls for evaluation after treatment for 24 months, with additional groups of 5 and 10 rats of each sex available after treatment for 6 and 12 months, respectively, while the EU or OECD guidelines require that: "each dose group and concurrent control group not intended for earlier sacrifice should contain at least 50 animals of each sex. A high dose satellite group for evaluation of pathology other than neoplasia should contain 20 animals of each sex, while the satellite control group would contain 10 animals of each sex"
• In this study, interim clinical examination was reported at 6, 12 and 24 months of treatment and not also at 3 and 18 months as required by the guidelines
• the survival of all groups was not at least 50% at 24 months, as is recommended by the guidelines for a negative test to be acceptable (EU testing Method B.33 (Annex V Directive 67/548/EEC -Combined chronic toxicity/carcinogenicity test).
Mortality. The mortality rates in treated groups (40 to 65% in males and 55 to 68% in females) were close to the mortality rates of controls (50 and 53% in males and females, respectively). Fig  1 and table 1 report the survival rate curves for the different groups of animals during the study period (0-24 months). The number of deaths throughout the administration period averaged 20 out of 40 animals in each group. The highest death rate was observed in females receiving the highest dose (2000 ppm) (27/40 corresponding to 68%) and the lowest death was noted in males at the same dosage (2000 ppm equal to 89.5 mg/kg bw/day). A survival of less than 50% was reported for the 5, 20 and 200 ppm treated groups in males and in all of the groups including controls in females.
Between the 13th and 16th months several animals from the control and treated groups died and then the death rate gradually increased. The highest mortality rate was seen between 22 and 24 months. The cumulative mortality rate showed no relationship with dose in either males or females. As is evident from table 1, the percent mortality by the end of 22 months of administration was less than 50% in all groups, in line with the survival rate required by the guidelines. Low survival rates in SD rats after two years is a common finding, with an average of only approx. 40% for many colonies (UK COC, 2000; Thayer and Foster, 2007) .
Clinical effects.
No treatment-related changes were noted in food efficiency, urinalysis, haematology, blood chemistry, phenolsulfophthalein (PSP) or bromosulfophthalein (BSP) excretion test (at 24 months) at any time of the observation. The PPR Panel concluded that the lack of data on clinical effects at 3 and 18 months does not prevent use of the study for evaluation of the long term effects induced by the test compound. This is particularly true of the carcinogenic potential of the compound. Indeed, the RMS considered this study adequate for the assessment of long term toxicity, suggesting that there were no major concerns about the sampling times.
Absolute and relative liver and thyroid weights were increased in males and females at 2000 ppm. Absolute liver weight increased in males by 20% at 52 weeks and by 17% at 104 weeks, and in females by 30% at 52 weeks and by 8% at 104 weeks. At 200 ppm, absolute liver weight was slightly increased (9%) in males at 52 weeks. An increase in relative kidney and heart weights was noted in females dosed at 200 and 2000 ppm for 24 months.
Liver lesions. Hypertrophy of hepatocytes associated with proliferation of smooth endoplasmic reticulum observed by electron microscopy was the main effect associated with buprofezin treatment. The increase in liver weight and the hepatocellular hypertrophy were present to a similar degree at 6, 12 and 24 months.
Re-examination of the liver changes using the current classification revealed that the only lesions significantly increased were centrilobular and diffuse hepatocellular hypertrophy in males of the 2000 ppm group and centrilobular hepatocellular hypertrophy in females of the 200 and 2000 ppm group. The number of females with diffuse hypertrophy and/or foci of cellular alteration in liver were 9, 7, 12, 17 and 21 at 0, 5, 20, 200 and 2000 ppm, respectively. The PPR Panel concluded that this finding indicated a mild to moderate hepatic effect for which the liver compensates physiologically by hypertrophy. No signs of liver structural damage were observed in any group. The hypertrophy of the hepatocytes was confirmed to be accompanied by proliferation of smooth endoplasmic reticulum by electron microscopy observation. A number of foci of cellular alteration were also scored, termed eosinophilic foci, homogenous basophilic foci and tigroid basophilic foci that are considered potentially pre-neoplastic lesions. However, none of these lesions showed a significant increase in frequency in any treated group except in the 200-ppm females.
Thyroid lesions.
There was no significant increase in thyroid neoplasia in males or females of any treated group compared with controls. Only two follicular cell carcinomas (in a 20 ppm and a 2000 ppm male) and one follicular cell adenoma (in a 2000 ppm female) were observed and these findings were considered incidental and not treatment related. The incidence of both follicular cell hypertrophy and C-cell hyperplasia were significantly elevated in males and females of the 2000-ppm group and the incidence of follicular cell hypertrophy was significantly elevated in males of the 200-ppm groups. The thyroid data from the re-examination report were presented as a function of time of termination, to examine evidence for time trends. In males, the dose trends for follicular cell hypertrophy are clear; there is, however, no evidence for a time trend. Thickening or hyperplasia of the thyroid follicular epithelium was significantly elevated in males and females at 2000 ppm. The findings in the thyroid, both in the original and reexamination reports, indicate that the thyroid was affected at the high dose of buprofezin.
Tumour incidence. There was no significant difference in the incidence or in the type of tumours in treated groups relative to the controls. There was some indication that mammary gland adenomas appeared earlier in treated females than in control females; the incidence was higher in treated animals that were killed in extremis or died during the study compared to control animals. However, there was no difference in total incidences of mammary tumours (the incidence of mammary gland adenocarcinoma was lower in the highest dose group compared to the control group). Atrophy of the prostate and seminal vesicles was seen slightly more often in rats at 2000 ppm but without statistical significance.
The study did not show any carcinogenic activity for buprofezin. The NOAEL was 20 ppm (equal to 0.90 mg/kg bw/day for males and 1.12 mg/kg bw/day for females), based on liver and thyroid effects.
Conclusions on Question 1
The PPR Panel concluded that the differences from the EU guidelines (EU testing Method B.33 (Annex V Directive 67/548/EEC) -Combined chronic toxicity/carcinogenicity test) in the carcinogenicity study in rats are not such as to prevent its use for the evaluation of the carcinogenic potential of the test compound.
Genotoxic and Carcinogenic Potential of Buprofezin in the Context of the Human Risk Assessment
The EFSA Journal (2007) 620, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] Two studies on carcinogenicity were conducted using SPF ICR-Crj mice and Sprague-Dawley rats. In mice and rats, neither the nature nor the incidence of tumours was affected by the administration of buprofezin. The PPR Panel concludes that buprofezin is not carcinogenic in rats or mice. The available battery of genotoxicity tests was considered adequate by JMPR, which reported: "Buprofezin did not have mutagenic properties when tested in a number of in vitro and in vivo systems, which included assessment of gene mutations, DNA damage, and clastogenic effects" (JMPR, 1991).
EPA based its evaluation of the genotoxic potential of buprofezin on the same battery of tests and expressed "no concern for mutagenic activity in several studies such as the Ames assay, forward mutation assay, mouse micronucleus assay, in vitro human cytogenetic assay, and unscheduled DNA synthesis" (EPA 2000)
Gene mutation
Buprofezin was tested up to maximum concentrations limited by cytotoxicity, and by the solubility of the test chemical under the conditions of culture. No significant increase in revertant colony numbers was observed in Salmonella typhimurium strains TA 1535, TA 1537, TA 1538, TA 98 or TA 100 at concentrations of 1.6, 8, 40, 200, 1000 and 5000 μg/plate in a vehicle of dimethyl sulphoxide in either the presence or absence of Aroclor-induced rat liver microsomal preparations (Callander, 1988) . The compound did not induce point mutations in L5178Y TK+/-mouse lymphoma cells at concentrations of 13.3, 17.8, 23.7, 31.6, 42.2, 56.3, 75 and 100 μg/ml in a vehicle of DMSO with and without S9 mix (Cross, 1988) .
DNA damage
The compound at a range of concentrations from 0.003 μg/ml to 3.05 μg/ml was inactive in a primary rat hepatocyte unscheduled DNA synthesis (UDS) assay (Trueman, 1988) .
Chromosomal effects

In vitro chromosomal aberration test in peripheral human lymphocytes
Buprofezin at concentrations of 10, 60 and 100 μg/ml growth medium in a vehicle of dimethyl sulphoxide did not induce chromosomal damage in human lymphocytes after 3 hours of treatment in vitro in the presence or absence of Aroclor-induced rat liver microsomal preparation.
The test substance was tested to the limits of its solubility. No relevant toxic effects at the highest concentration were detected, except for a reduction of the mitotic index (65% and 69% without metabolic activation and 41% and 89% of controls with metabolic activation in lymphocytes from donor 1 and donor 2 respectively) (Howard et al., 1988 ).
This study was not considered acceptable by the RMS because a number of deviations from the EU guidelines were identified:
• The short period of treatment (3 h). The EU guidelines state that in the event of a negative result, as in this study, the test should be repeated using a continuous treatment without S-9 mix until sampling at a time equivalent to about 1.5 times the normal cell cycle length.
• The lack of a highest concentration producing adequate toxicity (>50% reduction in mitotic index). This point is questionable because higher concentrations were not possible due to the limited solubility of the compound. Greater toxic effects would be achievable only by longer periods of treatment.
• The number of metaphases scored was 100 instead of 200 as established by the guideline.
Genotoxic and Carcinogenic Potential of Buprofezin in the Context of the Human Risk Assessment
The EFSA Journal (2007) 620, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] • No data on aneuploidy were reported.
Peripheral blood lymphocytes cannot be considered the best in vitro system for the evaluation of genotoxic effects due to the high interindividual variability in baseline frequencies, which impairs the use of historical controls, and in their susceptibility to mutagens.
In vivo bone marrow micronucleus assay
Buprofezin was also tested in vivo in a micronucleus test in mouse bone marrow using a protocol according to EU guidelines.
Six male and female BDF1 mice per group were given buprofezin in 2% Tween 80 solution by gastric intubation at doses of 6400, 8000 and 10000 mg/kg bw as a single treatment. Mitomycin C was used as the positive control. Two separate experiments were performed to evaluate the effects at different times after treatment. In the first, which included the highest dose groups at 10000 mg/kg, and positive and negative controls, bone-marrow smears were prepared 12, 24, 48 and 72 hours after administration. In the second experiment, which included the intermediate dose groups of 6400 and 8000 mg/kg bw and concurrent controls, the smears were prepared 24 hours after dosage. A further experiment was carried out at the highest dose of 10000 g/kg/day, given every 24 h for 4 days. In this treatment group, the number of animals was increased to 8, because deaths of some animals were anticipated. This supplemental study was carried out using all the doses with both sexes and a sampling time only of 24 hours.
No significant decrease in PCE (polychromatic erythrocytes) to total erythrocytes ratio, as an indicator of toxicity, was observed. A significant increase in the frequency of micronucleated PCE (MN-PCE) was detected only after 24 hours and not at 48 and 72 hours after treatment in both sexes at 10000 mg/kg (p< 0.05) and in male mice at 6400 (p< 0.05) and 8000 (p<0.01) mg/kg after 24 hours of treatment compared with the concurrent controls (Table 3b ).
The increase in the incidence of MN-PCE was not confirmed in the supplementary study. In addition, the observed effect cannot be considered toxicologically significant, when compared with the historical control MN frequency. No effect was observed at the highest dosage when administered on four consecutive occasions. Under the conditions of this study the test compound did not induce a reproducible increase in micronuclei frequency in mouse bone marrow up to and including the highest dose tested on acute and subacute administration (Sasaki, 1983) .
The study was accepted by the RMS as providing only additional information because the results of the first experiment were considered equivocal. A new study (with identification of the presence or absence of a kinetochore or centromeric DNA in the micronuclei) was requested to explore the mechanism of action for the potential chromosomal effect of the compound. This request may have been prompted by the evidence from the open literature of an aneugenic effect of the compound in vitro. 
Studies from the open literature
Two papers were identified in the open literature concerning the clastogenic activity of buprofezin. The evidence from these studies suggests a potential effect on chromosomes but they do not fulfil the criteria of study acceptability and have other significant limitations. Hence, they are of only very limited value in the evaluation of the genotoxic activity of buprofezin.
a. In vitro genotoxicity study in Syrian hamster embryo cells (SHE)
Buprofezin was studied in vitro at concentrations from 3.81 -30.5 µg/ml in Syrian hamster embryo cells (SHE) with a battery of tests: morphological cell transformation, DNA repair synthesis by the bromodeoxyuridine density-shift method, and micronuclei frequency using antikinetochore antibodies.
At the concentrations tested for a period of 5 hours, the compound reduced colony-forming ability by 20%. Concentrations ranging from 3.81-15.3 µg/ml induced 2 transformed colonies/1000 scored colonies and 9/1000 at 30.5 µg/ml. Due to the small magnitude of this effect, it is considered equivocal.
No effect on DNA repair synthesis was detected at the tested concentration levels.
At the concentrations tested, from 3.81 to 30.5 µg/ml , a statistically significant increase in micronuclei frequency was observed starting from 3.81 µg/ml (16/1000 vs. 11/1000 in controls) with a concentration-response relationship. The analysis using anti-kinetochore antibodies revealed a 5-fold increase in the frequency of positive micronuclei (70% kinetochore positive (KC+) -MN at 30.5 µg/ml vs. 12% KC+-MN in untreated cells) without any significant change in the percentage of negative micronuclei (Herrera et al., 1993) .
This study, in addition to lacking a number of the criteria for acceptability, such as adherence to good laboratory practice, does not report sufficient details of the methods and shows some inconsistency in the results obtained, mainly the low percentage of the detected KC+-MN in the control group (12%), about half of the frequency observed in the literature with this cell line (e.g. Dopp et al., 1995) .
b. In vivo study
Buprofezin was also tested in vivo for the induction of chromosomal aberrations in both somatic and germ cells of male mice in comparison with the organophosphorous insecticide profenfos after single oral treatment at 1/4, 1/8 and 1/16 LD 50 for each compound.
Buprofezin was administered as formulation 25% SC, supplied by ICI Agrochemicals.
Male Swiss mice were treated at very high doses of the formulation (from 0.79 to 2.8 g/kg bw) because the fractions of the LD 50 were based on the active ingredient. Samples from bone marrow and testes were taken 24 h post-treatment.
A statistically significant increase in mean percentage of abnormal metaphases, calculated including or excluding gaps, was detected in bone marrow cells at the doses of 1.4 and 2.8 g/kg body wt corresponding to 1/8 and 1/16 LD 50 . The incidence of chromosomal effects, mainly expressed as chromatid-type aberrations was about twice the control level at the highest dose. No effect was observed in germ cells at the same dose levels. (Fahmy and Abbala, 1998).
The magnitude of the observed effect can be considered low and cannot be attributed to buprofezin itself because the study evaluated a complex formulation containing only 25% of the active ingredient and a number of unspecified co-formulants that may modulate genotoxic activity.
New genotoxicity studies
The Notifier provided new genotoxicity studies carried out on the basis of the suggestion from the RMS: an in vitro chromosomal aberration test in cultured Chinese hamster lung cells and a new in vivo micronucleus test in mice.
In vitro chromosomal aberration test in cultured Chinese hamster lung cells (CHL)
This study is in accord with the EU-guideline and it was designed to assess the potential of buprofezin to induce both structural and numerical chromosomal aberrations.
Chinese hamster lung cells (CHL) were exposed for 6 hours to buprofezin at concentrations of 64.1, 70.6, 77.9 and 26.5, 31.8, 38.2 μg/ml growth medium in a vehicle of dimethyl sulphoxide with and without rat liver S9 mix, respectively and sampled at a time equivalent to about 1.5 normal cell cycle lengths (20 h) after the beginning of the treatment. Continuous exposure was also performed to buprofezin without S9 mix at concentrations of 10.9, 15.3, 21.4 and 7.79, 10.9, 15.3 μg/ml growth medium for 1.5 or 3 normal cell cycle lengths (20 and 40 h), respectively. 200 metaphases were scored for each concentration.
The highest concentrations of buprofezin, as determined in a preliminary experiment using a number of treatment times, reduced cell viability by approximately 50% without problems of precipitation in the cell medium. Precipitation of the compound was observed at 91.6 µg/ml or more, i.e. at a concentration above the cytotoxic dose. A comparison with the previous in vitro study carried out in peripheral human lymphocytes reveals that buprofezin was more toxic to established cultures of Chinese hamster cells and this allowed chromosomal damage to be evaluated at the highest tolerated concentration, without visible precipitation.
The incidence of chromosomal effects in positive and negative controls fell within the respective historical ranges, satisfying the conditions to validate the experiment. No increase in structural or numerical chromosomal aberrations was detected at any concentration of the test compound or conditions of treatment compared to the concurrent or historical controls (table 4A and 4B) . 
Genotoxic and Carcinogenic Potential of Buprofezin in the Context of the Human Risk Assessment
The EFSA Journal ( The study is in accord with the EU guidelines and was carried out to evaluate the potential clastogenic and aneugenic activity of the test compound in somatic cells.
In a first experiment, buprofezin (purity 98.2%) in olive oil was administered via oral gavage to Slc/ICR male mice (5 animals/group) once a day for two consecutive days at three dose levels 500, 1000 and 2000 mg/kg. The highest dose of 2000 mg/kg was selected on the basis of clinical signs, such as hypolocomotion and polyuria, observed at 1000 and 3000 mg/kg. The positive control substances, mitomycin C and colchicine, were administered at 3 and 1 mg/kg by a single intraperitoneal injection, respectively. At 24 hours after final dosing, bone marrow cells were extracted and prepared for analysis. The smears were stained with acridine orange. 2000 immature erythrocytes per animal were scored for the incidence of micronucleated immature erythrocytes (MNIE). In order to evaluate bone marrow toxicity induced by the treatment, 200 total erythrocytes per animal were evaluated for the ratio of immature erythrocytes (IE)/total erythrocytes (TE). The criterion for scoring immature erythrocytes was the cytoplasm emitting red fluorescence. Micronuclei were identified as small bodies emitting yellowish green fluorescence as did the main nuclei.
A statistically significant increase in the mean frequency of MNIE was detected only at the highest dose (2000 mg/kg), with a mean frequency of 20.2 ± 12.3‰ compared with 1.5 ± 0.6 ‰ for the control group (almost 13.5-fold increase). The frequencies of MNIE at the lower doses were comparable to the negative control frequency. Hence, it was not possible to determine the relationship, if any, between the induction of MNIE and dose. The positive controls, mitomycin C and colchicine induced statistically significant increases in the frequency of micronucleated immature erythrocytes, satisfying the conditions to validate the experiment.
A second experiment included only the highest dose, because it was designed to address mainly the mechanism of action of the observed chromosomal damage, by the use of CREST antikinetochore antibody. Propidium iodide was used as a counterstain for the DNA of nuclei and micronuclei.
The results of this experiment showed a statistically significant increase in mean frequency of micronuclei in immature erythrocytes. The frequency of MNIE was 3.4 ± 1.0‰, about a 3-fold increase compared to the control level. The frequency of kinetochore positive micronuclei in the 2000 mg/kg buprofezin group was slightly increased but not statistically significantly compared with the vehicle control value (31.6 ± 6.7% compared to 24.0 ± 6.5% in controls). Colchicine, which is aneugenic, induced a statistically significant increase in the kinetochore positive MNIE frequency. On the other hand, mitomycin C, which is clastogenic, induced a statistically significant decrease in the frequency.
On the whole the results of the study have to be classified as equivocal and provide only very limited information for the evaluation of the genotoxicity of buprofezin for the following reasons:
• No criteria for MN scoring were reported, except for the fluorescence emission (yellowish green fluorescence same as nuclei)
• It was not possible to establish dose-dependency of the increase in frequency of micronuclei observed in the first experiment, because only the highest dose resulted in a significant response. In such a case a confirmatory test is required using the same or optimized test conditions. The second experiment cannot be considered as a confirmatory test because it was carried out at only a single dose using a different methodology.
• The mean frequency of MNIE in concurrent positive controls is higher in the first experiment (69.5 ± 11.7 MNIE/1000 IEs) compared to the second one (46.5 ± 7.7 MNIE/1000 IEs), evidencing the difference between the two different scoring methods applied in the main experiment and in the second one. The use of propidium iodide, counterstain for the DNA in the second experiment, presents advantages compared to acridine orange: the fluorescence is long lasting and longer than AO (Dias et al., 2005) • Individual data for MNIE/1000 cells (24.0, 33.5, 6.5, 8.0, 29.0) for buprofezin 2000 mg/kg in the first experiment, reveal a large interindividual variability.
• A very large historical positive control range (mitomycin C, 3 mg/kg) calculated from the data for 8 animals in the experimental period 1999-2005 was shown in the original report 10.0-167.2 MNIE/1000 IEs
•
The results of the present study cannot exclude an aneuploidogenic mechanism, mediated by indirect effects, to explain the increase in the frequency of MNIE induced by high doses of buprofezin, as was suggest by the published in vitro study (Herrera et al., 1993) . The mechanism for any induction of MN by buprofezin was not adequately addressed in the present study. Only one experiment including 5 animals was carried out to evaluate the kinetochore positive MN and no historical control values were reported for the % of KC+MN evaluated by the CREST method. In addition the experimental evidence indicates that fluorescence in situ hybridization (FISH) combining centromeric and telomeric probes is the most accurate technique to evaluate the composition of MN (Kirsch-Volders et al., 1997) . The CREST approach does not allow evaluation of dysfunction in components of the mitotic apparatus affecting the kinetochore, the experimental method is not adequately standardized and in some cases it produces equivocal results (Miller et al., 1991 , SchrieverSchwemmer and Adler., 1994 , Surrales et al., 1995 .
A document on the evaluation of the results obtained in this study was presented by the Notifier. This report concludes that the increase in cytogenetic damage, observed only at very high doses of the compound, is attributable to effects other than a genotoxic action, referring to a previous report on the hypothermic effect of buprofezin when administered orally at 1000-3000 mg/kg using olive oil as vehicle. A dose-dependent decrease of rectal temperature, maximally about 1.5 degrees Celsius, was observed at both 1000 and 3000 mg/kg but not at lower doses, reaching a maximal response at 2-3 hours after dosing (Sugimoto, 1982) . In support of this mechanism for the induction of MNIE by buprofezin, a document from the UK Committee on Mutagenicity of Chemicals in Food, Consumer Products and the Environment COM/03/S5-November 2003 is cited.
There is an increasing body of evidence that some disturbances in the physiology of treated animals can give rise to increases in cytogenetic effects in the bone marrow that are not due to any direct compound-induced genotoxic damage. An analysis recently carried out by the International Workshop on Genotoxicity Testing (IWGT) working group indicates that compounds that cause either significant increases or decreases in core body temperature for a sustained period, may induce increases in micronucleated PCEs (Tweats et al., 2007a,b) . An increase in the frequency of micronuclei in immature erythrocytes was observed, as described in a series of reported examples, with a decrease of body temperature for sustained periods of time (24-48 hours). The decrease of body temperature induced by high doses of buprofezin persisted for only 2-3 hours, starting 2-3 hours after dosing. In addition, the scientific evidence has demonstrated that a change in body temperature appears to explain an increase in the frequency of micronuclei to no more than 3 times that of the control value.
A possible explanation for this effect of hypothermia is a reduction in the oxygen tension of the blood, stimulating erythropoietin release and increased cell division of erythroblasts, increasing the number of cells undergoing enucleation. In a series of examples it was reported that the size distribution of micronuclei was such that there was a prevalence of large micronuclei, suggesting the presence of a whole chromosome originating from disruption of chromosomal attachment to the spindle. The evidence from the in vivo micronucleus study with buprofezin in which no increase in kinetochore positive micronuclei was observed, does not support this mechanism. 
Conclusions on Question2
The PPR Panel concluded on the basis of an adequate range of suitably conducted tests of genotoxicity both in vitro and in vivo that there is no evidence that buprofezin is genotoxic. It is the view of the Panel that the recent in vivo micronucleus test on bone marrow is not interpretable and does not contribute to the evaluation of the genotoxicity of buprofezin. The PPR Panel concludes that the toxicological database on the carcinogenicity and genotoxicity of buprofezin is sufficient for setting reference values.
After long term exposure in rats and mice, no compound-related carcinogenic effects were evident.
Buprofezin did not show any genotoxic potential in an acceptable, comprehensive battery of in vitro and in vivo tests evaluating different genetic endpoints of genotoxic damage (gene mutation, chromosome mutation, DNA damage and repair) using bacteria and mammalian systems. Table 6 summarises the results and NOAELs and LOAELs determined from short term and long term toxicity and carcinogenicity studies.
On the basis of its consideration of genotoxic and carcinogenic potential of buprofezin, the PPR Panel concludes, that there is no reason to deviate from the use of a safety factor of 100 in establishing reference values. 
CONCLUSIONS AND RECOMMENDATIONS
The PPR Panel re-evaluated the long-term toxicity/carcinogenicity and genotoxicity studies on buprofezin.
Two studies on the carcinogenicity of buprofezin were conducted using SPF ICR-Crj mice and Sprague-Dawley rats. In mice and rats, neither the nature nor the incidence of tumours was affected by the administration of buprofezin. The PPR Panel concluded that the differences from the EU guidelines in the carcinogenicity study in rats noted by RMS, were not such as to prevent its use for the evaluation of the carcinogenic potential of the test compound.
Buprofezin did not show any genotoxic potential in an acceptable, comprehensive battery of in vitro and in vivo tests evaluating different genetic endpoints of genotoxic damage (gene mutation, chromosome mutation, DNA damage and repair) using bacteria and mammalian systems. A new in vitro chromosomal aberration test in cultured Chinese hamster lung cells (CHL) did not show any increase in structural or numerical chromosomal aberrations at any concentration of buprofezin, up to those that were cytotoxic, compared to the concurrent or historical controls. It is the view of the Panel that a recent in vivo micronucleus test of buprofezin on bone marrow is not interpretable and does not contribute to the evaluation of the genotoxicity of buprofezin.
The PPR Panel concludes that the toxicological database on the carcinogenicity and genotoxicity of buprofezin is sufficient for setting reference values. 
GLOSSARY / ABBREVIATIONS
Aneuploidy: a change in chromosome number from the normal diploid or haploid number for the species.
CREST antibodies: antibodies to kinetochore proteins obtainable from the serum of patients with the calcinosis/Raynauld's phenomenon/esophageal dysmotility/sclerodactyly /teleangiectesia (CREST) variant of scleroderma Kinetochore :protein structure in eukaryotes which assembles on the centromere and links the chromosome to microtubule polymers from the mitotic spindle during mitosis and meiosis.
